Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

At Stocks Down Under, it has been a while since we've looked at Ozempic and other GLP-1 Drugs. Investors paid a lot of attention to them in 2023, particularly those invested in companies with potential to be impacted directly or indirectly. The industry has come a fair way in the past couple of years and…

ByNick SundichJanuary 6, 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look At in the year ahead! What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] Stocks Down Under's Top 10 Hottest ASX Stocks to Look At in 2026! Note: These…

ByNick SundichJanuary 2, 2026

Monash IVF (ASX:MVF) Plunges 15% as $312m Takeover Bid Collapses- Is This a Buying Opportunity?

Monash IVF: Is This a Buying Opportunity? Monash IVF (ASX: MVF) shares crashed 15% to 69.5 cents last week after Soul Patts and Genesis Capital abruptly withdrew their A$312 million takeover bid. The consortium gave no explanation for walking away from the 80-cent offer that Monash's board had rejected as "opportunistic" just four weeks ago.…

ByUjjwal MaheshwariDecember 29, 2025

Our 5 ASX Predictions for 2026!

This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert will happen. It has become an annual tradition of ours, and some of these calls we get right, others we don't. Arguably our boldest call in suggesting ANZ would be the best performing big 4…

ByNick SundichDecember 24, 2025

Invion (ASX:IVX) Surges 20% on Non-Dilutive Funding for Cancer Program

Invion Secures Non-Dilutive Backing to Advance Cancer Therapy Invion (ASX:IVX) saw a sharp rerating today, with the share price rising 20% following the announcement of potential non-dilutive funding that meaningfully changes the near-term risk profile of the business. Rather than issuing new shares to advance its oesophageal cancer program, Hanlim Pharm will fund the required preclinical…

ByCharlie YouldenDecember 23, 2025

Is Pro Medicus (ASX:PME) a Buy After the 34% Pullback?

Pro Medicus slips, growth momentum remains Pro Medicus (ASX: PME) has dropped approximately 34% from its record high of A$336 in July 2025 and now trades near A$222. Investors are asking if Australia’s top-performing stock has finally slowed down. For context, this company has delivered 54,000 per cent returns over 15 years, making it a…

ByUjjwal MaheshwariDecember 23, 2025

Regis Healthcare (ASX:REG) Drops Below $7.20 on CEO Exit: A Buying Opportunity?

Regis Healthcare CEO Exit: What Investors Watch Next Regis Healthcare (ASX: REG) shares fell 2.6% to A$7.13 after CEO Dr Linda Mellors announced her resignation to pursue a career opportunity in a different industry. The departure ends a six-year tenure that transformed Regis Healthcare from a struggling business into one of the ASX's best-performing healthcare…

ByUjjwal MaheshwariDecember 23, 2025

Is Telix Pharmaceuticals (ASX:TLX) Now Undervalued With Phase 3 China Clinical Success?

Why Telix Pharmaceuticals Pullback Could Be a Second Chance Telix Pharmaceuticals (ASX:TLX) has faced a challenging year, particularly for a company that previously delivered consistently strong growth. Disclosure issues and delays around FDA progress for its brain cancer imaging asset have clearly weighed on sentiment and reset near term expectations. As a result, the stock…

ByCharlie YouldenDecember 22, 2025

Telix Pharmaceuticals (ASX:TLX) Down 55% Amid Lawsuit: Is It Time to Buy or Sell?

Telix Pharmaceuticals (ASX: TLX) has been crushed in 2025. The stock has fallen roughly 55% from its February high of A$32 to around A$12.50 today. The damage came from three blows: an SEC subpoena in July, an FDA Complete Response Letter (CRL) in August, and now a US class action lawsuit. We believe this selloff…

ByUjjwal MaheshwariDecember 17, 2025

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

Neuren Pharmaceuticals (ASX: NEU) rose 2.5% yesterday after the US FDA approved DAYBUE STIX, a new powder formulation of its Rett syndrome treatment. The stock has surged 47% over the past year, significantly outperforming the broader ASX, and now trades at a market capitalisation of around AUD 2.55 billion. For investors watching the healthcare space,…

ByUjjwal MaheshwariDecember 16, 2025